Treatment with FDA-approved ‘senolytic’ compounds dasatinib and quercetin significantly alleviates pro-inflammatory cytokines, reducing Aβ accumulation in APP/PS1 AD mice [7]. The gene discussed is APP; the disease is Alzheimer disease.